Carboplatin in Advanced Endometrial Carcinoma: NCT07198074 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 28 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 3
Clinical phase
Recruiting
Recruitment status
255
Planned enrollment
2028-07-01
Primary-completion proxy
Executive view
NCT07198074 evaluates Carboplatin in Advanced Endometrial Carcinoma. The disclosed sponsor is National Cancer Institute, the design is Interventional, and the geographic footprint is United States. The first listed primary endpoint is Progression-free survival (PFS), assessed over From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07198074 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Advanced Endometrial Carcinoma landscape. Drug & Asset MCP drug_fetch was queried for Carboplatin, while Company & Deal Intelligence MCP organization_fetch was queried for National Cancer Institute.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07198074 | Carboplatin | Phase 3 / Recruiting | National Cancer Institute | United States | Progression-free survival (PFS) From study entry to time of progression or death, whichever occurs fi… | 2028-07-01 |
| NCT07278986 | Pafolacianine | Early Phase 1 / Recruiting | Abramson Cancer Center | United States | Primary Endpoint 2 months after surgery | 2027-10-01 |
| NCT07262619 | EIK-1005 | Phase 1/2 / Recruiting | Eikon Therapeutics, Inc. | Singapore, United States, Portugal, Spain, New Zealand, South Korea, Austria, Belgium, Norway, Finland, Poland, Italy, Australia, Germany | Dose-Limiting Toxicity (DLT) - Part 1 21 Days | 2029-03-01 |
| NCT07227168 | Pembrolizumab | Phase 1 / Recruiting | Sutro Biopharma, Inc. | United States | Part 1A: Number of participants with Dose-limiting Toxicities (DLTs) Up to Day 21 | 2027-12-01 |
| NCT07216105 | Trastuzumab | Phase 1 / Recruiting | Fate Therapeutics, Inc. | United States | Number of participants with dose limiting toxicities (DLTs) From Day 1 through Day 29 of Cycle 1( each cycle is 56 days) | 2028-01-01 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07198074 is a Phase 3, recruiting study with 255 planned participants. Allocation is Randomized, masking is None (Open Label), and the intervention model is Parallel Assignment.
The primary endpoint is “Progression-free survival (PFS)” over “From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years.” The retrieved endpoint description is: Will be defined using Response Evaluation Criteria in Solid Tumors version (v) 1.1. Will be tested using one-sided log-rank tests with α-levels stratified by factors used in the randomization. Patients will be grouped by their randomized treatment assignment for intention-to-treat (ITT) analyses, supported by patients in ITT population. Treatment hazard ratios and their 95% confidence intervals will be estimated using a Cox proportional hazards models specified with a main effect for the randomized treatment assignment and stratified using the stratification factors applied at randomization..
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 255 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
The protocol identifies Carboplatin, Paclitaxel, Pembrolizumab as control therapy. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Advanced Endometrial Carcinoma. These records do not establish direct evidence for NCT07198074 unless the registration number matches.
Phase II Study of Fulvestrant in Combination With Abemaciclib in Hormone Receptor Positive Adenocarcinoma of Endometrium
Phase 2; n=27; ORR = 44 percentage of participants (90% Confidence Interval, 27.0 - 62.1) Source: https://clinicaltrials.gov/ct2/show/results/NCT03643510
A Phase 1b/2, Open-Label, Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab for Participants With Advanced Unresectable and/or Metastatic Immune Checkpoint Inhib…
Phase 1/2; n=97; Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0 = 62 Participants ; Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0 = 3 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT05572684
A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma
Phase 2; n=62; CBR = 27 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT01797523
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Carboplatin is indexed as Small molecule drug with DNA biology and a global stage of Approved. The asset profile lists Corden Pharma GmbH as an originator or developer.
National Cancer Institute is indexed in United States with the website http://www.cancer.gov. The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of eleven agencies. The record lists 205 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Carboplatin is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07198074
Protocol source: https://clinicaltrials.gov/study/NCT07198074
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 28 September 2026.
Carboplatin in Advanced Endometrial Carcinoma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Progression-free survival (PFS) and 2028-07-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
